Cell surface complex of cathepsin B/annexin II tetramer in malignant progression

Biochimica et Biophysica Acta - Protein Structure and Molecular Enzymology

Volumn 1477, Issue 1-2, 2000, Pages 215-230

  Mai, Jianxin ^a   Waisman, David M ^b   Sloane, Bonnie F ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Cancer Biology Research Group   (Canada)

Author keywords

Annexin II tetramer; Cathepsin B; Extracellular proteolysis; Malignant progression; Proteolytic center; Serine protease

Indexed keywords

CATHEPSIN B; LIPOCORTIN 2; SERINE PROTEINASE;

CARCINOGENESIS; CELL INVASION; CELL MOTILITY; CELL SURFACE; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; HUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; TUMOR CELL;

ANIMALS; ANNEXIN A2; CATHEPSIN B; EXTRACELLULAR MATRIX PROTEINS; HUMANS; MEMBRANE PROTEINS; NEOPLASM METASTASIS; NEOPLASMS; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 0034615565     PISSN: 01674838     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-4838(99)00274-5     Document Type: Review

References (147)

1. Liotta L.A., Rao C.N., Barsky S.H. Tumor invasion and the extracellular matrix. Lab. Invest. 49:1983;636-649.
2. Mignatti P., Robbins E., Rifkin D.B. Tumor invasion through the human amniotic membrane: requirement for a proteinase cascade. Cell. 47:1986;487-498.
3. Garcia M., Platet N., Liaudet E., Laurent V., Derocq D., Brouillet J.P., Rochefort H. Biological and clinical significance of cathepsin D in breast cancer metastasis. Stem Cells. 14:1996;642-650.
4. Chambers A.F., Matrisian L.M. Changing views of the role of matrix metalloproteinases in metastasis. J. Natl. Cancer Inst. 89:1997;1260-1270.
5. DeClerck Y.A., Imren S., Montgomery A.M., Mueller B.M., Reisfeld R.A., Laug W.E. Proteases and protease inhibitors in tumor progression. Adv. Exp. Med. Biol. 425:1997;89-97.
6. Johnsen M., Lund L.R., Romer J., Almholt K., Dano K. Cancer invasion and tissue remodeling: common themes in proteolytic matrix degradation. Curr. Opin. Cell. Biol. 10:1998;667-671.
7. Lochter A., Sternlicht M.D., Werb Z., Bissell M.J. The significance of matrix metalloproteinases during early stages of tumor progression. Ann. NY Acad. Sci. 23:1998;180-193.
8. Yan S.-Q., Sameni M., Sloane B.F. Cathepsin B and human tumor progression. Biol. Chem. 379:1998;113-123.
9. Rao R.N. Targets for cancer therapy in the cell cycle pathway. Curr. Opin. Oncol. 8:1996;516-524.
10. Roldan A.L., Cubellis M.V., Masucci M.T., Behrendt N., Lund L.R., Dano K., Appella E., Blasi F. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J. 9:1990;467-474.
11. Hajjar K.A., Jacovina A.T., Chacko J. An endothelial cell receptor for plasminogen/tissue plasminogen activator. I. Identity with annexin II. J. Biol. Chem. 296:1994;21191-21197.
12. Nomura H., Sato H., Seiki M., Mai M., Okada Y. Expression of membrane-type matrix metalloproteinase in human gastric carcinomas. Cancer Res. 55:1995;3263-3266.
13. Okumura Y., Sato H., Seiki M., Kido H. Proteolytic activation of the precursor of membrane type 1 matrix metalloproteinase by human plasmin. A possible cell surface activator. FEBS Lett. 402:1997;181-184.
14. Kobayashi H., Schmitt M., Goretzki L., Chucholowski N., Calvete J., Kramer M., Gunzler W.A., Janicke F., Graeff H. Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (pro-uPA). J. Biol. Chem. 266:1991;5147-5152.
15. Kobayashi H., Moniwa N., Sugimura M., Shinohara H., Ohi H., Terao T. Effects of membrane-associated cathepsin B on the activation of receptor-bound prourokinase and subsequent invasion of reconstituted basement membranes. Biochim. Biophys. Acta. 1178:1993;55-62.
16. Llano E., Pendas A.M., Freije J.P., Nakano A., Knauper V., Murphy G., Lopez-Otin C. Identification and characterization of human MT5-MMP, a new membrane-bound activator of progelatinase a overexpressed in brain tumors. Cancer Res. 59:1999;2570-2576.
17. Sameni M., Elliott E., Ziegler G., Fortgens P.H., Dennison C., Sloane B.F. Cathepsins B and D are localized at surface of human breast cancer cells. Pathol. Oncol. Res. 1:1995;43-53.
18. Sloane B.F., Rozhin J., Johnson K., Taylor H., Crissman J.D., Honn K.V. Cathepsin B: association with plasma membrane in metastatic tumors. Proc. Natl. Acad. Sci. USA. 83:1986;2483-2487.
19. Choi K.S., Ghuman J., Kassam G., Kang H.M., Fitzpatrick S.L., Waisman D.M. Annexin II tetramer inhibits plasmin-dependent fibrinolysis. Biochemistry. 37:1998;648-655.
20. H.-M. Kang, K.S. Choi, G. Kassam, S.L. Fitzpatrick, M. Kwon, G.A. Grant, A.Z. Eisen, G.I. Goldberg, The role of annexin II tetramer in plasminogen activation. Trends Cardiovasc. Med. (1999) (in press).
21. Wirl G., Schwartz-Albiez R. Collagen-binding proteins of mammary epithelial cells are related to Ca2(+)- and phospholipid-binding annexins. J. Cell. Physiol. 144:1990;511-522.
22. Chung C.Y., Erickson H.P. Cell surface annexin II is a high affinity receptor for the alternatively spliced segment of tenascin-C. J. Cell Biol. 126:1994;539-548.
23. Poole A.R., Tiltman K.J., Recklies A.D., Stoker T.A.M. Differences in the secretion of the proteinase cathepsin B at the edges of human breast carcinomas and fibroadenomas. Nature. 273:1980;545-547.
24. Recklies A.D., Tiltman K.J., Stoker T.A.M., Poole A.R. Secretion of proteinases from malignant and nonmalignant human breast tissue. Cancer Res. 40:1980;550-556.
25. Mort J.S., Leduc M., Recklies A. A latent thiol proteinase from ascitic fluid of patients with neoplasia. Biochim. Biophys. Acta. 662:1981;173-180.
26. Recklies A.D., Poole A.R., Mort J.S. A cysteine proteinase secreted from human breast tumors is immunologically related to cathepsin B. Biochem. J. 207:1982;633-636.
27. Sloane B.F., Dunn J.R., Honn K.V. Lysosomal cathepsin B: correlation with metastatic potential. Science. 212:1981;1151-1153.
28. Sloane B.F., Honn K.V., Sadler J.G., Turner W.A., Kimpson J.J., Taylor J.D. Cathepsin B activity in B16 melanoma cells: a possible marker for metastatic potential. Cancer Res. 42:1982;980-986.
29. Murnane M.J., Sheahan K., Ozdemirli M., Shuja S. Stage-specific increases in cathepsin B messenger RNA content in human colorectal carcinoma. Cancer Res. 51:1991;1137-1142.
30. Campo E., Munoz J., Nadal A., Jares P., Fernandez P.L., Pakein A., Emmert-Buck M., Sloane B., Cardesa A. Cathepsin B mRNA overexpression correlates with tumor progression in colorectal carcinomas. Lab. Invest. 72:1995;A58.
31. Rempel S.A., Rosenblum M.L., Mikkelsen T., Yan P.S., Ellis K.D., Golembieski W.A., Sameni M., Rozhin J., Ziegler G., Sloane B.F. Cathepsin B expression and localization in glioma progression and invasion. Cancer Res. 54:1994;6027-6031.
32. Campo E., Munoz J., Miquel R., Palacin A., Cardesa A., Sloane B.F., Emmert-Buck M. Cathepsin B expression in colorectal carcinomas correlates with tumor progression and shortened patient survival. Am. J. Pathol. 145:1994;301-309.
33. Mikkelsen T., Yan P.S., Ho K.L., Sameni M., Sloane B.F., Rosenblum M.L. Immunolocalization of cathepsin B in human glioma: implications for tumor invasion, angiogenesis. J. Neurosurg. 83:1995;285-290.
34. Sivaparvathi M., Sawaya R., Wang S.W., Rayford A., Yamamoto M., Liotta L.A., Nicolson G.L., Rao J.S. Overexpression and localization of cathepsin B during the progression of human gliomas. Clin. Exp. Metast. 13:1995;49-56.
35. Budihna M., Strojan P., Smid L., Skrk J., Vrhovec I., Zupevc A., Rudolf Z., Zargi M., Krasovec M., Svetic B., Kopitar-Jerala N., Kos J. Prognostic value of cathepsins B, H, L, D and their endogenous inhibitors stefins A and B in head and neck carcinoma. Biol. Chem. Hoppe-Seyler. 377:1996;385-390.
36. Abdollahi A., Getts L.A., Sonoda G., Miller P.D., Taguchi T., Godwin A.K., Testa J.R., Hamilton T.C. Genome scanning detects amplification of the cathepsin B gene (CtsB) in transformed rat ovarian surface epithelial cells. J. Soc. Gynecol. Invest. 6:1999;32-40.
37. Bova G.S., MacGrogan D., Levy A., Pin S.S., Bookstein R., Isaacs W.B. Physical mapping of chromosome 8p22 markers and their homozygous deletion in a metastatic prostate cancer. Genomics. 35:1996;46-54.
38. Hughes S.J., Glover T.W., Zhu X.X., Kuick R., Thoraval D., Orringer M.B., Beer D.G., Hanash S. A novel amplicon at 8p22-23 results in overexpression of cathepsin B in esophageal adenocarcinoma. Proc. Natl. Acad. Sci. USA. 95:1998;12410-12415.
39. Sinha A.A., Gleason D.F., DeLeon O.F., Wilson M.J., Sloane B.F. Localization of a biotinylated cathepsin B oligonucleotide probe in human prostate including invasive cells and invasive edges by in situ hybridization. Anat. Rec. 235:1993;233-240.
40. Visscher D.W., Sloane B.F., Sameni M., Babiarz J.W., Jacobson J., Crissman J.D. Clinicopathologic significance of cathepsin B immunostaining in transitional neoplasia. Mod. Pathol. 7:1994;76-81.
41. Visscher D.W., Sloane B., Sakr W., Sameni M., Weaver D., Bouwman D., Crissman J.D. Clinicopathologic significance of cathepsin B and urokinase-type plasminogen activator immunostaining in colorectal adenocarcinoma. Int. J. Surg. Pathol. 1:1994;227-234.
42. Sinha A.A., Wilson M.J., Gleason D.F., Reddy P.K., Sameni M., Sloane B.F. Immunohistochemical localization of cathepsin B in neoplastic human prostate. Prostate. 26:1995;171-178.
43. Frosch B.A., Berquin I., Emmert-Buck M.R., Moin K., Sloane B.F. Molecular regulation, membrane association and secretion of tumor cathepsin B. APMIS. 107:1999;28-37.
44. Emmert-Buck M.R., Roth M.J., Zhuang Z., Campo E., Rozhin J., Sloane B.F., Liotta L.A., Stetler-Stevenson W.G. Increased gelatinase A (MMP-2) and cathepsin B activity in invasive tumor regions of human colon cancer samples. Am. J. Pathol. 145:1994;1285-1290.
45. Maciewicz R.A., Wardale R.J., Etherington D.J., Paraskeva C. Immunodetection of cathepsins B and L present in and secreted from human pre-malignant and malignant colorectal tumour cell lines. Int. J. Cancer. 43:1989;478-486.
46. Ohsawa T., Higashi T., Tsuji T. The secretion of high molecular weight cathepsin B from cultured human liver cancers. Acta Med. Okayama. 43:1989;9-15.
47. Nishimura Y., Amano J., Sato H., Tsuji H., Kato K. Biosynthesis of lysosomal cathepsins B and H in cultured rat hepatocytes. Arch. Biochem. Biophys. 262:1988;159-170.
48. Rozhin J., Sameni M., Ziegler G., Sloane B.F. Pericellular pH affects distribution and secretion of cathepsin B in malignant cells. Cancer Res. 54:1994;6517-6525.
49. Honn K.V., Timar J., Rozhin J., Bazaz R., Sameni M., Ziegler G., Sloane B.F. A lipoxygenase metabolite, 12-(S)-HETE, stimulates protein kinase C-mediated release of cathepsin B from malignant cells. Exp. Cell Res. 214:1994;120-130.
50. Sloane B.F., Moin K., Sameni M., Tait L.R., Rozhin J., Ziegler G. Membrane association of cathepsin B can be induced by transfection of human breast epithelial cells with c-Ha-ras oncogene. J. Cell Sci. 107:1994;373-384.
51. Shuja S., Murnane M.J. Marked increases in cathepsin B and L activities distinguish papillary carcinoma of the thyroid from normal thyroid or thyroid with non-neoplastic disease. Int. J. Cancer. 16:1996;420-426.
52. Guenette R.S., Mooibroek M., Wong K., Wong P., Tenniswood M. Cathepsin B, a cysteine protease implicated in metastatic progression, is also expressed during regression of the rat prostate and mammary glands. Eur. J. Biochem. 226:1994;311-321.
53. Emmert-Buck M.R., Karustis D.G., Day N.A., Honn K.V., Sloane B.F. Degradation of extracellular-matrix proteins by human cathepsin B from normal and tumor tissues. Biochem. J. 282:1992;273-278.
54. Lah T.T., Buck M.R., Honn K.V., Crissman J.D., Rao N.C., Liotta L.A., Sloane B.F. Degradation of laminin by human tumor cathepsin B. Clin. Exp. Metast. 7:1989;461-468.
55. Ugarova T.P., Ljubimov A.V., Deng L., Plow E.F. Proteolysis regulates exposure of the IIICS-1 adhesive sequence in plasma fibronectin. Biochemistry. 35:1996;10913-10921.
56. Eeckhout Y., Vaes G. Further studies on the activation of procollagenase, the latent precursor of bone collagenase. Biochem. J. 166:1977;21-31.
57. Khan A., Krishna M., Baker S.P., Malhothra R., Banner B.F. Cathepsin B expression and its correlation with tumor-associated laminin and tumor progression in gastric cancer. Arch. Pathol. Lab. Med. 122:1998;172-177.
58. Higashiyama M., Doi O., Kodama K., Yokouchi H., Tateishi R. The prognostic implications of the cathepsin B expression in pulmonary adenocarcinomas. Jpn. J. Cancer Clin. 37:1991;1151-1157.
59. Sukoh N., Abe S., Ogura S., Isobe H., Takekawa H., Inoue K., Kawakami Y. Immunohistochemical study of cathepsin B. Prognostic significance in human lung cancer. Cancer. 74:1994;46-51.
60. Higashiyama M., Doi O., Kodama K., Yokouchi H., Tateishi R. Cathepsin B expression in tumour cells and laminin distribution in pulmonary adenocarcinoma. J. Clin. Pathol. 46:1993;18-22.
61. Khan A., Kirshna M., Baker S.P., Malhothra R., Banner B.F. Cathepsin B and tumor-associated laminin expression in the progression of colorectal adenoma to carcinoma. Mod. Pathol. 46:1998;18-22.
62. Sloane B.F. Suicidal tumor proteases. Nature Biotechnol. 14:1996;826-827.
63. Moin K., Cao L., Day N.A., Koblinski J.E., Sloane B.F. Tumor cell membrane cathepsin B. Biol. Chem. 379:1998;1093-1099.
64. Murata M., Miyashita S., Yokoo C., Tamai M., Hanada K., Hatayama K., Towatari T., Nikawa T., Katunuma N. Novel epoxysuccinyl peptides: selective inhibitors of cathepsin B, in vitro. FEBS Lett. 280:1991;307-310.
65. Linebaugh B.E., Sameni M., Day N.A., Sloane B.F., Keppler D. Exocytosis of active cathepsin B: enzyme activity at pH 7.0, inhibition and molecular mass. Eur. J. Biochem. 264:1999;100-109.
66. Morgan O.R., Fernandez M.P. Annexin gene structures and molecular evolutionary genetics. Cell. Mol. Life Sci. 53:1997;508-511.
67. Waisman D.M. Annexin II tetramer: structure and function. Mol. Cell. Biochem. 149/150:1995;301-322.
68. Mollenhauer J. Annexins: what are they good for? Cell. Mol. Life Sci. 53:1997;506-507.
69. Moss S.E. Annexins. Trends Cell Biol. 7:1997;87-89.
70. Raynal P., Pollard H.B. Annexins: the problem of assessing the biological role for a gene family of multifunctional calcium- and phospholipid-binding proteins. Biochim. Biophys. Acta. 1197:1994;63-93.
71. Jindal H.K., Chaney W.G., Anderson C.W., Davis R.G., Vishwanatha J.K. The protein-tyrosine kinase substrate, calpactin I heavy chain (p36), is part of the primer recognition protein complex that interacts with DNA polymerase alpha. J. Biol. Chem. 266:1991;5169-5176.
72. Weber K., Gerke V. Identity of p36K phosphorylated upon Rous sarcoma virus transformation with a protein purified from brush borders; calcium-dependent binding to non-erythroid spectrin and F-actin. EMBO J. 3:1984;227-233.
73. Erikson E., Tomasiewicz H.G., Erikson R.L. Biochemical characterization of a 34-kilodalton normal cellular substrate of pp60v-src and an associated 6-kilodalton protein. Mol. Cell Biol. 4:1984;77-85.
74. Glenney J. Two related but distinct forms of the Mr 36,000 tyrosine kinase substrate (calpactin) that interact with phospholipid and actin in a Ca2+-dependent manner. Proc. Natl. Acad. Sci. USA. 83:1986;4258-4262.
75. Glenny J.R., Woodgett J.R., Isacke C.M., Hunter T. Association of the S-100-related calpactin I light chain with the NH2-terminal tail of the 36-kDa heavy chain. J. Biol. Chem. 261:1986;10485-10488.
76. Johnsson N., Marriott G., Weber K. p36, the major cytoplasmic substrate of src tyrosine protein kinase, binds to its p11 regulatory subunit via a short amino-terminal amphiphatic helix. EMBO J. 7:1988;2435-2442.
77. Johnson N., Vandekerckhove J., Van-Damme J., Weber K. Binding sites for calcium, lipid and p11 on p36, the substrate of retroviral tyrosine-specific protein kinases. FEBS Lett. 198:1986;361-364.
78. 2+-binding sites. J. Cell Sci. 103:1992;733-742.
79. Burgoyne R.D. Calpactin in exocytosis. Nature. 331:1988;20.
80. Gruenberg J., Emans N. Annexin II is a major component of fusogenic endosomal vesicles. Trends Cell Biol. 3:1993;224-227.
81. Robitzki A., Schroder H.C., Ugarkovic D., Gramzow M., Fritsche U., Batel R., Muller W.E. cDNA structure and expression of calpactin, a peptide involved in Ca2(+)-dependent cell aggregation in sponges. Biochem. J. 271:1990;415-420.
82. Schafer B.W., Heizmann C.W. The S100 family of EF-hand calcium-binding proteins: functions and pathology. Trends Biochem. Sci. 21:1996;134-140.
83. Weber K., Gerke V. The regulatory chain in the p36-kd substrate complex of viral tyrosine-specific protein kinases is related in sequence to the S-100 protein of glial cells. EMBO J. 4:1985;2917-2920.
84. Tokumitsu H., Mizutani A., Minami H., Kobayashi R., Hidaka H. A calcyclin-associated protein is a newly identified member of the Ca2+/phospholipid-binding proteins, annexin family. J. Biol. Chem. 267:1992;8919-8924.
85. Mailliard W.S., Haigler H.T., Schlaepfer D.D. Calcium-dependent binding of S100C to the N-terminal domain of annexin I. J. Biol. Chem. 271:1996;719-725.
86. Seemann J., Weber K., Osborn M., Pardon R.G., Gerke V. The association of annexin I with early endosomes is regulated by Ca2+ and requires an intact N-terminal domain. Mol. Biol. Cell. 7:1996;1359-1374.
87. Rety S., Sopkova J., Renouard M., Osterloh D., Gerke V., Tabaries S., Russo-Marie F., Lewit-Bentley A. The crystal structure of a complex of p11 with the annexin II N-terminal peptide. Nature Struct. Biol. 6:1999;89-95.
88. Engelkamp D., Schafer B.W., Mattei M.G., Erne P., Heizmann C.W. Six S100 genes are clustered on human chromosome 1q21: identification of two genes coding for the two previously unreported calcium-binding proteins S100D and S100E. Proc. Natl. Acad. Sci. USA. 9:1993;6547-6551.
89. Cochran A.J., Lu H.F., Li P.X., Saxton R., Wen D.R. S-100 protein remains a practical marker for melanocytic and other tumours. Melanoma Res. 3:1993;325-330.
90. Davies B.R., Davies M.P., Gibbs F.E., Barraclough R., Rudland P.S. Induction of the metastatic phenotype by transfection of a benign rat mammary epithelial cell line with the gene for p9Ka, a rat calcium-binding protein, but not with the oncogene EJ-ras-1. Oncogene. 8:1993;999-1008.
91. Keutzer J.C., Hirschhorn R.R. The growth-regulated gene 1B6 is identified as the heavy chain of calpactin I. Exp. Cell Res. 188:1990;153-159.
92. Vellucci V.F., Germino F.J., Reiss M. Cloning of putative growth regulatory genes from primary human keratinocytes by subtractive hybridization. Gene. 166:1995;213-220.
93. Chiang Y., Schneiderman M.H., Vishwanatha J.K. Annexin II expression is regulated during mammalian cell cycle. Cancer Res. 53:1993;6017-6021.
94. Vishwanatha J.K., Chiang Y., Kumble K.D., Hollingsworth M.A., Pour P.M. Enhanced expression of annexin II in human pancreatic carcinoma cells and primary pancreatic cancers. Carcinogenesis. 14:1993;2575-2579.
95. Kumble K.D., Hirota M., Pour P.M., Vishwanatha J.K. Enhanced levels of annexins in pancreatic carcinoma cells of Syrian hamsters and their intrapancreatic allografts. Cancer Res. 52:1992;163-167.
96. Cole S.P., Pinkoski M.J., Bhardwaj G., Deeley R.G. Elevated expression of annexin II (lipocortin II, p36) in a multidrug resistant small cell lung cancer cell line. Br. J. Cancer. 65:1992;498-502.
97. Reeves S.A., Chavez-Kappel C., Davis R., Rosenblum M., Isreal M.A. Developmental regulation of annexin II (lipocortin 2) in human brain and expression in high grade glioma. Cancer Res. 52:1992;6871-6876.
98. Roseman B.J., Bollen A., Hsu J., Lamborn K., Isreal M.A. Annexin II marks astrocytic brain tumors of high histologic grade. Oncol. Res. 6:1994;561-567.
99. Chiang Y., Davis R.G., Vishwanatha J.K. Altered expression of annexin II in human B-cell lymphoma cell lines. Biochim. Biophys. Acta. 1313:1996;295-301.
100. Frohlich M., Motte P., Galvin K., Takahashi H., Wands J., Ozturk M. Enhanced expression of the protein kinase substrate p36 in human hepatocellular carcinoma. Mol. Cell. Biol. 10:1990;3216-3223.
101. Harder T., Thiel C., Gerke V. Formation of the annexin II2p112 complex upon differentiation of F9 teratocarcinoma cells. J. Cell Sci. 104:1993;1109-1117.
102. Fox M.T., Prentice D.A., Hughes J.P. Increases in p11 and annexin II proteins correlate with differentiation in the PC12 pheochromocytoma. Biochem. Biophys. Res. Commun. 177:1991;1188-1193.
103. Aarli A., Skeie J.T., Kristoffersen E.K., Bakke A., Ulvestad E. Inhibition of phytohaemagglutinin-induced lymphoproliferation by soluble annexin II in sera from patients with renal cell carcinoma. APMIS. 105:1997;699-704.
104. Halder T., Pawelec G., Kirkin A.F., Zeuthen J., Meyer H.E., Kun L., Kalbacher H. Isolation of novel HLA-DR restricted potential tumor-associated antigens from the melanoma cell line FM3. Cancer Res. 57:1997;3238-3244.
105. Li K., Adibzadeh M., Halder T., Kalbacher H., Heinzel S., Muller C.Zeuthen,J., Pawelec G. Tumour-specific MHC-class-II-restricted responses after in vitro sensitization to synthetic peptides corresponding to gp100 and annexin II eluted from melanoma cells. Cancer Immunol. Immunother. 47:1998;32-38.
106. Yeatman T.J., Updyke T.V., Kaetzel M.A., Dedman J.R., Nicolson G.L. Expression of annexins on the surfaces of non-metastatic and metastatic human and rodent tumor cells. Clin. Exp. Metastasis. 11:1993;37-44.
107. Nicolson G.L. Cancer metastasis: tumor cell and host organ properties important in metastasis to specific secondary sites. Biochim. Biophys. Acta. 948:1988;175-224.
108. Nicolson G.L. Tumor and host molecules important in the organ preference of metastsis. Semin. Cancer Biol. 2:1991;143-154.
109. Tressler R.J., Updyke T.V., Yeatman T., Nicolson G.L. Extracellular annexin II is associated with divalent cation-dependent tumor cell-endothelial cell adhesion of metastatic RAW117 large-cell lymphoma cells. J. Cell. Biochem. 53:1993;265-276.
110. Mignatti P., Rifkin D.B. Release of basic fibroblast growth factor, an angiogenic factor devoid of secretory signal sequence: a trivial phenomenon or a novel secretion mechanism? J. Cell. Biochem. 47:1991;201-207.
111. Siever D.A., Erickson H.P. Extracellular annexin II. Int. J. Biochem. Cell Biol. 29:1997;1219-1223.
112. J.L. Blum, M.E. Zeigler, M.S. Wicha, Cellular and Molecular Biology of Mammary Cancer, Plenum Press, New York, 1987, pp. 105-128.
113. Erickson H.P., Bourdon M.A. Tenascin: an extracellular matrix protein prominent in specialized embryonic tissues and tumors. Annu. Rev. Cell Biol. 5:1989;71-92.
114. Chiquet-Ehrismann R., Mackie E.J., Pearson C.A., Sakakura T. Tenascin: an extracellular matrix protein involved in tissue interactions during fetal development and oncogenesis. Cell. 47:1986;131-139.
115. Koukoulis G.K., Gould V.E., Bhattacharyya A., Could J.E., Howeedy A.A., Virtanen I. Tenascin in normal, reactive, hyperplastic, and neoplastic tissues: biologic and pathologic implications. Hum. Pathol. 22:1991;636-643.
116. Chuong C.M., Chen H.M. Enhanced expression of neural cell adhesion molecules and tenascin (cytotactin) during wound healing. Am. J. Pathol. 138:1991;427-440.
117. Lightner V.A., Erickson H.P. Binding of hexabrachion (tenascin) to the extracellular matrix and substratum and its effect on cell adhesion. J. Cell Sci. 95:1990;263-277.
118. Mackie E.J., Thesleff I., Liverani D. Induction of tenascin in healing wounds. J. Cell Biol. 107:1988;2757-2767.
119. Whitby D.J., Ferguson M.W. The extracellular matrix of lip wounds in fetal, neonatal and adult mice. Development. 112:1991;651-668.
120. Daniloff J.K., Crossin K.L., Pincon-Raymond M., Murawsky M., Rieger F., Edelman G.M. Expression of cytotactin in the normal and regenerating neuromuscular system. J. Cell Biol. 108:1989;625-635.
121. Gatchalian C.L., Schachner M., Sanes J.R. Fibroblasts that proliferate near denervated synaptic sites in skeletal muscle synthesize the adhesive molecules tenascin (J1), N-CAM, fibronectin, and a heparan sulfate proteoglycan. J. Cell Biol. 108:1989;1873-1890.
122. Chung C.Y., Murphy-Ullrich J.E., Erickson H.P. Mitogenesis, cell migration and loss of focal adhesion induced by tenascin-C interacting with its cell surface receptor, annexin II. Mol. Biol. Cell. 7:1996;883-892.
123. Alexander C.M., Werb Z. Proteinases and extracellular matrix remodeling. Curr. Opin. Cell Biol. 1:1989;974-982.
124. Ossowski L., Clunie G., Masucci M.T., Blasi F. In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion. J. Cell Biol. 115:1991;1107-1112.
125. Overall C.M., King A.E., Sam D.K., Ong A.D., Lau T.T.Y., Wallon U.M., DeClerck Y.A., Atherstone J. Identification of the tissue inhibitor of metalloproteinases-2 (TIMP-2) binding site on the hemopexin carboxyl domain of human gelatinase A by site-directed mutagenesis. The hierarchical role in binding timp-2 of the unique cationic clusters of hemopexin modules iii and iv. J. Biol. Chem. 274:1999;4421-4429.
126. Nakamura H., Ueno H., Yamashita K., Shimada T., Yamamoto E., Noguchi M., Fujimoto N., Sato H., Seiki M., Okada Y. Enhanced production and activation of progelatinase A mediated by membrane-type 1 matrix metalloproteinase in human papillary thyroid carcinomas. Cancer Res. 59:1999;467-473.
127. Hajjar K.A. The endothelial cell tissue plasminogen activator receptor. Specific interaction with plasminogen. J. Biol. Chem. 266:1991;21962-21970.
128. Hajjar K.A., Hamel N.M. Identification and characterization of human endothelial cell membrane binding sites for tissue plasminogen activator and urokinase. J. Biol. Chem. 265:1990;2908-2916.
129. Kassam G., Choi K.S., Ghuman J., Kang H.M., Fitzpatrick S.L., Zackson T., Zackson S., Toba M., Shinomiya A., Waisman D.M. The role of annexin II tetramer in the activation of plasminogen. J. Biol. Chem. 273:1998;4790-4799.
130. Kassam G., Le B.H., Choi K.S., Kang H.M., Fitzpatrick S.L., Louie P., Waisman D.M. The p11 subunit of the annexin II tetramer plays a key role in the stimulation of t-PA-dependent plasminogen activation. Biochemistry. 37:1998;16958-16966.
131. Paciucci R., Tora M., Diaz V.M., Real F.X. The plasminogen activator system in pancreas cancer: role of t-PA in the invasive potential in vitro. Oncogene. 16:1998;625-633.
132. Matrisian L.M., Bowden G.T. Stromelysin/transin and tumor progression. Semin. Cancer Biol. 1:1990;107-115.
133. Dalet-Fumeron V., Boudjennah L., Pagano M. Competition between plasminogen and procathepsin B as a probe to demonstrate the in vitro activation of procathepsin B by the tissue plasminogen activator. Arch. Biochem. Biophys. 335:1996;351-357.
134. Monsky W.L., Chen W.T. Proteases of cell adhesion proteins in cancer. Semin. Cancer Biol. 4:1993;251-258.
135. Monsky W.L., Kelly T., Lin C.Y., Yeh Y., Stetler-Stevenson W.G., Mueller S.C., Chen W.T. Binding and localization of M(r) 72, 000 matrix metalloproteinase at cell surface invadopodia. Cancer Res. 53:1993;3159-3164.
136. Monsky W.L., Lin C.Y., Aoyama A., Kelly T., Akiyama S.K., Mueller S.C., Chen W.T. A potential marker protease of invasiveness, seprase, is localized on invadopodia of human malignant melanoma cells. Cancer Res. 54:1994;5702-5710.
137. Mueller S.C., Chen W.T. Cellular invasion into matrix beads: localization of beta 1 integrins and fibronectin to the invadopodia. J. Cell Sci. 2:1991;213-225.
138. Aoyama A., Chen W.T. A 170-kDa membrane-bound protease is associated with the expression of invasiveness by human malignant melanoma cells. Proc. Natl. Acad. Sci. USA. 87:1990;8296-8300.
139. Carriero M.V., Del Vecchio S., Franco P., Potena M.I., Chiaradonna F., Botti G., Stoppelli M.P., Salvatore M. Vitronectin binding to urokinase receptor in human breast cancer. Clin. Cancer Res. 3:1997;1299-1308.
140. Hoyer-Hansen G., Behrendt N., Ploug M., Dano K., Preissner K.T. The intact urokinase receptor is required for efficient vitronectin binding: receptor cleavage prevents ligand interaction. FEBS Lett. 420:1997;79-85.
141. Wei Y., Yang X., Liu Q., Wilkins J.A., Chapman H.A. A role for caveolin and the urokinase receptor in integrin-mediated adhesion and signaling. J. Cell Biol. 144:1999;1285-1294.
142. Stahl A., Mueller B.M. The urokinase-type plasminogen activator receptor, a GPI-linked protein, is localized in caveolae. J. Cell Biol. 129:1995;335-344.
143. Schnitzer J.E., Liu J., Oh P. Endothelial caveolae have the molecular transport machinery for vesicle budding, docking, and fusion including VAMP, NSF, SNAP, annexins, and GTPases. J. Biol. Chem. 270:1995;14399-14404.
144. Lee T.L., Lin Y.C., Mochitate K., Grinnell F. Stress-relaxation of fibroblasts in collagen matrices triggers ectocytosis of plasma membrane vesicles containing actin, annexins II and VI, and beta 1 integrin receptors. J. Cell. Sci. 105:1993;167-177.
145. Nakahara H., Nomizu M., Akiyama S.K., Yamada Y., Yeh Y., Chen W.T. A mechanism for regulation of melanoma invasion. Ligation of alpha6beta1 integrin by laminin G peptides. J. Biol. Chem. 271:1996;27221-27224.
146. Lavie Y., Fiucci G., Liscovitch M. Up-regulation of caveolae and caveolar constituents in multidrug-resistant cancer cells. J. Biol. Chem. 273:1998;32380-32383.
147. Yang G., Truong L.D., Timme T.L., Ren C., Wheeler T.M., Park S.H., Nasu Y., Bangma C.H., Kattan M.W., Scardino P.T., Thompson T.C. Elevated expression of caveolin is associated with prostate and breast cancer. Clin. Cancer Res. 4:1998;1873-1880.